Clinical Trials

53 enrolled 11 charts

Phase 2 Active not recruiting

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT04238624 2025-07-02

Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer

16 enrolled

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT06978400 2025-05-18

A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer

64 enrolled

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT06119789 2025-03-26

MATRIX-Rare

96 enrolled

Other neoplasm

Rare Malignant Neoplasm

NCT06739395 2024-12-18

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

300 enrolled

Other solid neoplasm

Solid Tumor

NCT06482086 2024-12-05

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

75 enrolled

Locally Advanced Thyroid Gland Carcinoma

NCT04310397 2024-10-30

Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma

4 enrolled 8 charts

Melanoma

NCT06653517 2024-10-22

NETCAM

12 enrolled

Ameloblastoma

NCT05159245 2024-07-15

FINPROVE

Other hematologic neoplasm

250 enrolled

Hematologic Neoplasms

NCT06362694 2024-04-12

Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy

10 enrolled

Thyroid Carcinoma, Anaplastic

NCT04739566 2024-03-25

ANAPLAST-NEO

Phase 2 Withdrawn

Thyroid Carcinoma, Anaplastic

NCT05525273 2024-02-14

Swecranio

25 enrolled

CNS

Craniopharyngioma

NCT02367859 2024-01-30

Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma

1 enrolled 5 charts

Ameloblastoma, Adamantinoma

NCT02925234 2024-01-24

DRUP

1,550 enrolled

Neoplasms

NCT05876806 2023-11-30

Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations

30 enrolled

Neoplasms

NCT05182931 2023-10-31

I-FIRST

80 enrolled

Thyroid Neoplasms

NCT06079333 2023-10-12

NEO-ATACT

20 enrolled

Thyroid Carcinoma, Anaplastic

NCT04059224 2023-09-26

TraMel-WT

45 enrolled

Melanoma

NCT05299580 2023-09-14

"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"

Phase 2 Withdrawn

Melanoma

NCT02858921 2023-08-30

Neo Trio

60 enrolled

Melanoma, Neoplasms

NCT03563729 2023-07-13

MEMBRAINS

80 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT04619316 2023-06-22

ERRITI

70 enrolled

Thyroid Neoplasms

NCT02052193 2022-12-19

Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study

8 enrolled

Melanoma

NCT03668431 2022-06-27

Dabrafenib + Trametinib + PDR001 In Colorectal Cancer

25 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT03239015 2022-03-04

Efficacy and Safety of Precision Therapy in Refractory Tumor

300 enrolled

Neoplasms

NCT04554680 2021-03-05

Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy

5 enrolled

Thyroid Neoplasms

NCT03352947 2020-12-08

INTERIM

79 enrolled

Melanoma

NCT03972046 2020-10-19

Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma

Phase 2 Withdrawn

Melanoma, Skin Neoplasms

NCT02410863 2020-10-14

BOTTOM

10 enrolled

Melanoma

NCT01682213 2020-05-26

Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation

23 enrolled 10 charts

Melanoma

NCT02142036 2019-03-13

MetAction

50 enrolled

Neoplasm Metastasis

NCT02296996 2019-01-23

Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients

25 enrolled

Melanoma

NCT01721603 2018-01-23

Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets

2 enrolled 7 charts

Melanoma

NCT02625337 2017-09-15

IMPemBra

32 enrolled

Melanoma

NCT01701037 2017-06-23

Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery

13 enrolled 13 charts

Melanoma

NCT01619774 2016-12-12

An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor

28 enrolled 7 charts